International CCN Society, Paris, France,
J Cell Commun Signal. 2012 Aug;6(3):181-4. doi: 10.1007/s12079-012-0174-2. Epub 2012 Aug 3.
A critical look at a recently published manuscript reporting the role of CCN3 in the regulation of clear cell renal cell carcinoma (RCC) biology raises several scientific concerns, and reveals flaws in the reviewing process which appear to have resulted in the dissemination of conclusions that are not supported by proper experimental procedures. In the example presented here, the observed biological effects are attributed to a high molecular weight "CCN3" protein which is detected by a single commercial antibody that was not shown in the experimental conditions used by the authors to be a valid reagent capable of stringently detecting the "canonical" CCN3 protein. Experiments establishing that inhibiting the production of high molecular weight "CCN3" protein would reverse these biological effects were not performed. The case discussed here clearly demonstrates that unreliable data can go through peer reviewing and be published. As the data can end up being cited and used as a potential reference by new investigators in the field, we believe that such data can throw roadblocks across the scientific path of inquiry and mislead investigations. We therefore raise awareness for the need of a more stringent peer reviewing process in which assurance can be had that the strength and precision of the data have been thoroughly checked by experts in the CCN field, and previous work properly referenced.
对最近发表的一篇报道 CCN3 在透明细胞肾细胞癌 (RCC) 生物学调控中作用的手稿进行批判性分析,提出了一些科学问题,并揭示了审稿过程中的缺陷,这些缺陷似乎导致了传播的结论没有得到适当实验程序的支持。在本文所呈现的例子中,观察到的生物学效应归因于一种高分子量的“CCN3”蛋白,该蛋白被一种单一的商业抗体检测到,而在作者使用的实验条件下,该抗体并未被证明是一种能够严格检测“典型”CCN3 蛋白的有效试剂。没有进行抑制高分子量“CCN3”蛋白产生的实验来验证这些生物学效应是否会逆转。这里讨论的情况清楚地表明,不可靠的数据可以通过同行评审并发表。由于这些数据最终可能被引用并被该领域的新研究人员用作潜在参考,我们认为,这些数据可能会给科学研究带来障碍,并误导研究。因此,我们呼吁需要更严格的同行评审过程,以确保 CCN 领域的专家对数据的可靠性和精确性进行了彻底检查,并对以前的工作进行了适当的引用。